Literature DB >> 3025767

The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug.

A J Wood, G M Goodwin, R De Souza, A R Green.   

Abstract

The pharmacokinetic characteristics of lithium and the profile of plasma lithium concentration at steady state in both the mouse and the rat have been determined. The half life of lithium in both rodents was shorter (3.5 h and 6 h) than that found during maintenance therapy in man. Following a loading dose (10 mmol/kg s.c.) and twice daily maintenance injections (3 mmol/kg s.c.) of lithium chloride the plasma concentration remained above the accepted human therapeutic minimum (0.4 mM) for 16 of every 24 h in the mouse and throughout the entire 24 h period in the rat. Maximum concentrations in both species were below the range at which toxic effects might be expected to occur.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025767     DOI: 10.1016/0028-3908(86)90149-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  26 in total

1.  Lithium-induced decrease of brain inositol and increase of brain inositol-1-phosphate is transient.

Authors:  M R Hirvonen; K Savolainen
Journal:  Neurochem Res       Date:  1991-08       Impact factor: 3.996

2.  Optical drug monitoring: photoacoustic imaging of nanosensors to monitor therapeutic lithium in vivo.

Authors:  Kevin J Cash; Chiye Li; Jun Xia; Lihong V Wang; Heather A Clark
Journal:  ACS Nano       Date:  2015-01-21       Impact factor: 15.881

3.  Estimation of bioavailability on a single occasion after semisimultaneous drug administration.

Authors:  M O Karlsson; U Bredberg
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

4.  Acute, but not chronic, exposure to d-cycloserine facilitates extinction and modulates spontaneous recovery of a conditioned taste aversion.

Authors:  G Andrew Mickley; Jennifer L Remus; Linnet Ramos; Gina N Wilson; Orion R Biesan; Kyle D Ketchesin
Journal:  Physiol Behav       Date:  2011-09-10

5.  Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus.

Authors:  Theun de Groot; Anne P Sinke; Marleen L A Kortenoeven; Mohammad Alsady; Ruben Baumgarten; Olivier Devuyst; Johannes Loffing; Jack F Wetzels; Peter M T Deen
Journal:  J Am Soc Nephrol       Date:  2015-11-16       Impact factor: 10.121

6.  Lithium protects against glucocorticoid induced neural progenitor cell apoptosis in the developing cerebellum.

Authors:  Omar Cabrera; Joseph Dougherty; Sukrit Singh; Brant S Swiney; Nuri B Farber; Kevin K Noguchi
Journal:  Brain Res       Date:  2013-12-19       Impact factor: 3.252

7.  Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment.

Authors:  Michelle Mo; Ildiko Erdelyi; Klara Szigeti-Buck; Jennifer H Benbow; Barbara E Ehrlich
Journal:  FASEB J       Date:  2012-08-13       Impact factor: 5.191

8.  PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats.

Authors:  I Verbaeys; F León-Tamariz; H Pottel; E Decuypere; Q Swennen; M Cokelaere
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

9.  Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex.

Authors:  E Acquas; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

10.  No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS.

Authors:  Alan Gill; Joshua Kidd; Fernando Vieira; Kenneth Thompson; Steven Perrin
Journal:  PLoS One       Date:  2009-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.